Drug addiction is a devastating condition that affects the quality of the user and their families. In this podcast series, we explore the behaviors of individuals who abuse opioids and stimulants, and learn about their patterns of use and motivations to compel them to continue using these drugs through a series of candid interviews with opioid and stimulant recreational drug users.
In this episode, "Chasing the Dragon - A Series of Candid Interviews with Opioid and Stimulant Recreational Drug Users", moderated by Dr. Beatrice Setnik, CSO, and featuring Dr. Debra Kelsh, psychiatrist and Principal Investigator at Altasciences, we provide a unique perspective around the behaviors of opioid and stimulant drug abuse. Throughout the episode, Dr. Kelsh and Dr. Setnik will offer commentary on key moments from the interview with a drug user.
Navigate the discussion with these timestamps:
- 0:00:06 - Introduction by Dr. Beatrice Setnik, CSO
- 0:01:07 - Interviewee (male, aged 30) provides his personal history with opioid abuse
- 0:10:20 - Dr. Kelsh and Dr. Setnik commentary: early childhood exposure and adolescent use
- 0:16:53 - Interviewee continues to share his personal history with various drug use (access, usage, quitting/withdrawal)
- 0:43:03 - Dr. Kelsh and Dr. Setnik commentary: economics of drug use, exposure to various types of drugs, tampering with prescription drugs, and different degrees of addiction.
- 0:56:06 - Interviewee continues to share his personal experience with participating in clinical trials, withdrawal symptoms, and the economics of drug abuse
- 1:08:36 - Final commentary from Dr. Kelsh and Dr. Setnik: Managing withdrawal during clinical trials
Altasciences offers leading preclinical and clinical sites for substance use disorders, one of our key therapeutic areas of clinical trials, including expertise across a wide variety of mechanisms of action. Our experience in general toxicology, safety pharmacology, and clinical pharmacology covers a wide range of compounds, including oral, IM, IV, and implanted products. We also analyze a number of biomarkers and efficacy outcomes using visual analogue scales (VAS) and questionnaires. Our robust database of patients combined with our upscale facilities enable us to deliver rapid enrolment and excellent retention rates. Our sites have controlled substance licenses, including a DEA Schedule I.
Altasciences is an integrated drug development solution company, offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to their preclinical and clinical study needs. From lead candidate selection to proof of concept, we offer one-stop integrated formulation, preclinical and clinical manufacturing and analytical services. For over 25 years, Altasciences has been integrating into clients’ projects to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements.
Altasciences… helping sponsors get better drugs to the people who need them, faster. Visit our website to learn more: www.altasciences.com/